Symbols

CYTO(Delisted)

Altamira·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CYTO

Altamira Therapeutics Ltd.

A developer of RNA therapeutics for allergy and viral infections, and inner ear disorders

Industry

Established Date

Listing Date

08/06/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.altamiratherapeutics.com

Security Type

Common stock

Office address

Clarendon House, 2 Church Street, Hamilton HM11, Bermuda

Business

Introduction

Altamira Therapeutics Ltd. was established in 1998. The company's goal is to become a leading biomedical company focused on developing and commercializing RNA delivery technologies. The company believes that the use of RNA therapy, whether siRNA, mRNA or other types to control the expression of disease-associated genes, has great prospects. By utilizing the targets of small molecules and proteins that are "ineffective" in other aspects, it is expected to open up a new way of RNA therapy for the treatment of intractable diseases.

Company Financials

EPS

CYTO has released its 2022 Q1 earnings. EPS was reported at -1.43, versus the expected 0, missing expectations. The chart below visualizes how CYTO has performed over recent quarters, highlighting trends in earnings surprises.